4.7 Article

CD39-mediated ATP-adenosine signalling promotes hepatic stellate cell activation and alcoholic liver disease

Journal

EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 905, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.ejphar.2021.174198

Keywords

ATP; CD39; Hepatic stellate cell activation; TGF-beta/Smad3 pathway; Alcoholic hepatic disease

Funding

  1. National Natural Science Foundation of China [81970518]

Ask authors/readers for more resources

CD39 plays a role in alcoholic liver disease by regulating HSC activation and fibrosis development, and its blockade can prevent these processes. The findings suggest that ATP-adenosine signaling is a novel therapeutic target for alcoholic liver disease.
CD39 is associated with diverse physiological and pathological processes, including cell proliferation and differentiation. Adenosine triphosphate (ATP) is hydrolysed to adenosine by different enzymes including ectonucleoside triphosphate diphosphohydrolase-1/ENTPD1 (CD39) and ecto-5'-nucleotidase (CD73), regulating many physiological and pathological processes in various diseases, but these changes and functions in alcoholic liver disease are generally unknown. In this study, an alcoholic liver disease model in vivo was induced by ethanol plus carbon tetrachloride(CCl4) administered to C57BL/6 mice, who were the intraperitoneally injected with the CD39 inhibitor sodium polyoxotungstate (POM1) or colchicine from the 5th week to the 8th week. Meanwhile, hepatic stellate cells were stimulated by acetaldehyde to replicate alcoholic liver fibrosis models in vitro. Exogenous ATP and POM1 were added in turn to the culture system. Pharmacological blockade of CD39 largely prevents liver damage and collagen deposition. We found that blockade or silencing of CD39 prevented acetaldehyde-induced proliferation of HSC-T6 cells and the expression of fibrogenic factors. Moreover, blockade or silencing of CD39 could block the activation of the adenosine A2A and adenosine A2B receptors and the TGF-beta/Smad3 pathway, which are essential events in HSC activation. Thus, blockade of CD39 to inhibit the transduction of ATP to adenosine may prevent HSC activation, alleviating alcoholic hepatic fibrosis. The findings from this study suggest ATP-adenosine signalling is a novel therapeutic and preventive target for alcoholic liver disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available